The study can be criticized because it involved a highly selected group of patients, in that most patients at M.D. Anderson receive adjuvant therapy, such as tamoxifen or chemotherapy, says the study's lead researcher, Francisco J. Esteva, MD, PhD, associate professor of medicine.